首页> 外国专利> USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS

USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS

机译：重组人促红细胞生成素的基本形式在CAG重复突变治疗脊髓小脑型轴伤患者中的应用

页面导航

摘要
著录项
相似文献

摘要

Summary: ;The present invention relates to use of pharmaceutical compositions that have as active ingredient the basic form of recombinant human erythropoietin (rhEPO) and that are administered nasally for the treatment of spinocerebellar ataxia (SCA) with mutations of CAG repeats type, particularly of SCA type 2. Another object of the present invention is a method for stratifying patients into responders and non-responders to treatment with the basic form of rhEPO.

机译：摘要：本发明涉及具有作为活性成分的重组人促红细胞生成素（rhEPO）的基本形式并且经鼻给药以治疗具有CAG重复型，特别是SCA型突变的脊髓小脑共济失调（SCA）的药物组合物的用途。 2.本发明的另一个目的是一种将患者分为对rhEPO基本形式治疗的反应者和非反应者的方法。 展开▼

著录项

公开/公告号EP3473264A1

专利类型

公开/公告日2019-04-24

原文格式PDF

申请/专利权人 CENTRO DE INMUNOLOGIA MOLECULAR;
展开▼

申请/专利号EP20170740275

发明设计人 AMARO GONZÁLEZ DANIEL ENRIQUE;VELÁZQUEZ PÉREZ LUIS CLODOALDO;GARCÍA RODRÍGUEZ JULIO CÉSAR;RODRÍGUEZ LABRADA ROBERTO;SOSA TESTÉ ILIANA MARÍA;ORTEGA SÁNCHEZ RICARDO;HERNÁNDEZ CASAÑA PATRICIA;GONZÁLEZ TRIANA CONSUELO;JAY PÉREZ DANIEL;LÓPEZ MATILLA LIEN;JIMÉNEZ RODRÍGUEZ DAISE;
展开▼

申请日2017-06-08

分类号A61K38/18;G01N33/50;A61P25/28;

国家 EP

入库时间 2022-08-21 12:27:21

相似文献

专利

外文文献

中文文献

1. 硫氢化钠在制备治疗脊髓小脑性共济失调药物中的应用 [P] . 中国专利： CN107184596B . 2020.03.31

2. 硫氢化钠在制备治疗脊髓小脑性共济失调药物中的应用 [P] . 中国专利： CN107184596A . 2017-09-22

3. USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS [P] . EP3473264B1 . 2021-05-12

机译：使用CAG重复突变治疗纺丝脑共济失调患者的基本形式的重组人促红细胞生成素

4. USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF A PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS [P] . US2021060127A1 . 2021-03-04

机译：使用重组人促红细胞生成素的基本形式治疗纺丝夹虫患者与CAG重复突变的患者

5. Use of the basic form of recombinant human erythropoietin in the treatment of patients with spinocerebellar ataxia with CAG repeat mutations [P] . AU2017282933A1 . 2019-02-07

机译：重组人促红细胞生成素的基本形式在具有CAG重复突变的脊髓小脑共济失调患者中的应用

1. The humanδ2 glutamate receptor gene is not mutated in patients with spinocerebellar ataxia [J] . Jinxiang Huang, Aiyu Lin, Haiyan Dong, 中国神经再生研究（英文版） . 2014,第010期

2. Effect of recombinant human erythropoietin therapy on convalescent serological indicators in patients with severe craniocerebral injury [J] . Tian-Zhi Huang 海南医科大学学报（英文版） . 2017,第013期

3. Effect of recombinant human erythropoietin therapy on convalescent serological indicators in patients with severe craniocerebral injury [J] . Tian-Zhi Huang 海南医科大学学报(英文版) . 2017,第013期

4. Analysis of CAG repeats in SCA1, SCA2, SCA3, SCA6, SCA7 and DRPLA loci in spinocerebellar ataxia patients and distribution of CAG repeats at the SCA1, SCA2 and SCA6 loci in nine ethnic populations of eastern India. [J] . Basu P, Chattopadhyay B, Gangopadhaya PK, Human Genetics . 2000,第6期

5. Germ-line CAG repeat instability causes extreme CAG repeat expansion with infantile-onset spinocerebellar ataxia type 2. [J] . Tua Vinther-Jensen, Jakob Ek, Morten Duno, European journal of human genetics: EJHG . 2013,第6期

6. Expansion, mosaicism and interruption: mechanisms of the CAG repeat mutation in spinocerebellar ataxia type 1 [J] . Cara Kraus-Perrotta, Sarita Lagalwar Cerebellum & Ataxias . 2016,第1期

7. Comprehensive Analysis of Recombinant Human Erythropoietin Glycoforms by Capillary Electrophoresis and Nanoflow Liquid Chromatography Coupled with Middle-down Mass Spectrometry [C] . R. Viner, A. A. M. Heemskerk, D. M. Horn, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

8. Distinct Functional Effects of Kv3.3 Mutations Associated with Spinocerebellar Ataxia Type-13 [D] . Minassian, Natali Anne. 2010

9. Bioenergetics of the Calf Muscle in Friedreich Ataxia Patients Measured by 31P-MRS Before and After Treatment with Recombinant Human Erythropoietin [O] . Wolfgang Nachbauer, Sylvia Boesch, Rainer Schneider, -1

10. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin. [O] . Wolfgang Nachbauer, Sylvia Boesch, Rainer Schneider, 2013

11. Outcomes with the Use of Recombinant Human Erythropoietin in Critically Ill Burn Patients. [R] . Lundy, J. B., Hetz, K., Chung, K. K., 2010

1. Efficacy and safety of recombinant human erythropoietin(Hema-Plus®)for management of anemia in Thai patients on peritoneal dialysis [J] . Piyatida Chuengsaman ,Surapong Narenpitak ,Suchai Sritippayawan . 世界肾病学杂志:英文版 . 2021,第6期

2. Clinical Study of Recombinant Human Endostatin Combined with Iressa in Targeted Treatment of Patients with Lung Adenocarcinoma with Pleural Metastasis [J] . Yanbing Wang . 抗癌研究 . 2021,第004期

3. 不同补铁途径联合重组人促红细胞生成素治疗维持血液透析肾性贫血患者的疗效观察 [C] . 赵娜 ,王艺萍 . 2015临床急重症经验交流高峰论坛 . 2015

4. 中国东南部人群脊髓小脑性共济失调各基因亚型的频率与临床分析及利用自制CAG重复梯度分子量标记物检测千余中国人ATXN3的野生型CAG重复分布特征 [A] . 甘世锐 . 2010